Angiotensin Converting Enzyme 2 News and Research

RSS

COVID-19 mouse model could accelerate the search for treatments, vaccines

The global effort to quickly develop drugs and vaccines for COVID-19 has been hampered by limited numbers of laboratory mice that are susceptible to infection with SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

Examining the effect of smoking, nicotine and vaping on COVID-19 severity

Researchers at the University of Oxford say they will be conducting the most extensive study to date linking primary and clinical data for the assessment of associations between smoking status and the severity of coronavirus disease 2019 (COVID-19).

9 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Synthetic monoclonal antibodies effectively neutralize SARS-CoV-2 in laboratory conditions

In a new study available on the preprint server bioRxiv*, a multinational research group demonstrated how monoclonal antibodies strongly inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro at even sub-nanomolar concentrations. This makes them a prime candidate for the treatment of coronavirus disease (COVID-19).

8 Jun 2020

The receptor binding domain of the SARS-CoV-2

With the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across most of the world, scientists are working strenuously to find effective therapies or vaccines. Most strategies being worked on at present are targeting viral entry into the host cells, mainly through the interaction of the SARS-CoV-2 S protein with the angiotensin-converting enzyme 2 (ACE2) receptor.

8 Jun 2020

Inhibition of coronavirus spike protein binding to ACE2

A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.

8 Jun 2020

SARS-CoV-2 invasion of central nervous system through olfactory tract

As the COVID-19 pandemic continues to claim lives throughout the world, the evidence is mounting that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract as well as the central nervous system. Now, a new study by German researchers published on the preprint server bioRxiv in June 2020 describes various neurological manifestations of COVID-19, as well as the underlying pathophysiology.

7 Jun 2020

New strategy may facilitate development of multi-epitope peptide vaccine against SARS-CoV-2

By combining T and B lymphocyte analysis with manufacturability heuristic, researchers from the US and Germany proposed a set of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine peptides to use in subsequent animal studies and clinical trials. Their paper is currently available on the bioRxiv preprint server.

7 Jun 2020

Alpaca-derived antiviral agent neutralizes SARS-CoV-2

Researchers at Karolinska University Hospital and the University of Cape Town have identified an antibody fragment that targets the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and potently neutralizes the virus.

4 Jun 2020

Potential new immunotherapy for critical COVID-19

Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).

4 Jun 2020

Blood group type may affect susceptibility to COVID-19 respiratory failure

A group of over 120 researchers from various institutions across Europe has performed the first genome-wide association study to reveal host genetic factors that may contribute to respiratory failure in cases of coronavirus disease 209 (COVID-19).

3 Jun 2020

Scientists map how SARS-CoV-2 infects the airways

Now, in a significant scientific study, a team of researchers at the University of North Carolina Health Care (UNC) have mapped how SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19), infects the nasal cavity, the airways, and down to the lungs.

3 Jun 2020

SARS-CoV-2 can adversely affect cardiac cells and heart function

A research group from Germany demonstrated a direct toxic effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on cardiac cells in their paper published on the bioRxiv* preprint server. The finding warrants an in-depth analysis of cardiac tissue in certain coronavirus disease (COVID-19) patients, as well as close monitoring for any direct cardiomyocyte injury.

2 Jun 2020

SARS-CoV-2 emergence could be due to genetic selection and recombination

Researchers have found that genetic selection and recombination could be behind the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that leads to acute respiratory distress syndrome (ARDS) or COVID-19 disease. This research could explain COVID-19 pandemic and its emergence. The study titled, “Emergence of SARS-CoV-2 through recombination and strong purifying selection,” was published in the journal Science Advances.

1 Jun 2020

Study reveals how essential SARS-CoV-2 protein can be stabilized and scaled for production

A research group from the University of Texas in Austin described a high-yield production of a stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S-protein) that may accelerate the development of vaccines and diagnostic tests. This methodological 'tour de force' paper is currently available on the bioRxiv* preprint server.

1 Jun 2020

Study examines changes in prescription patterns during COVID-19 pandemic

A new study by investigators from Brigham and Women's Hospital examines changes in prescription patterns in the United States during the COVID-19 pandemic.

29 May 2020

A closer look at TMPRSS2: This could help treat COVID-19

The transmembrane protease serine-type 2 (TMPRSS2) protein plays a key role in COVID-19 infection since it primes the viral spike protein to allow viral entry into the target cell. A new study by researchers at Imperial College London and published on the preprint server bioRxiv in May 2020 describes the protein, which could be an attractive drug target to help manage COVID-19.

28 May 2020

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

Ryan Denomme, the CEO of Nicoya, speaks to News-Medical on their SARS-CoV-2 research using their SPR technology.

From Nicoya Lifesciences 28 May 2020

ACE2 receptors in the kidney not linked to high BP or RAS blockers

Even as the COVID-19 pandemic continues to smolder and flare up in various parts of the world, researchers are still trying to make sense of the virus, its routes of spread, its target tissues, and the immune responses it induces. One crucial piece of knowledge is that the primary viral receptor is a human enzyme called angiotensin-converting enzyme 2 (ACE2).

27 May 2020

Study shows children and adults have a comparable expression of SARS-CoV-2 entry-related genes

A recent paper by researchers from China demonstrated comparable expression levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry mediators in adults and children, suggesting that previously implied difference in viral-entry associated genes is likely not responsible for milder symptoms in children. The study is currently available on the medRxiv preprint server.

27 May 2020